Suresh S. Ramalingam

机构：Emory University, Cancer Institute (WIA), Piedmont Cancer Institute, AstraZeneca (Netherlands), AstraZeneca (Poland), Winship Cancer Institute · ORCID：0000-0002-0757-3106

发表论文 1235 篇 · 总被引 100625 次 · h-index 126

代表论文

Rapidly evolving therapeutic advances for classical EGFR-mutant NSCLC (2025 · Frontiers in Oncology · 被引 6)
Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion (2026 · Nature · 被引 4)
Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms (2026 · JCO Oncology Practice · 被引 2)
Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection (2026 · Proceedings of the National Academy of Sciences · 被引 1)
Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study (2026 · Clinical Cancer Research)
Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent (2026 · Science Advances)